Form 4: Assembly Biosciences Executive Equity Grant Disclosure
Statement of Changes in Beneficial Ownership
Jeanette M. Bjorkquist, PFO and PAO of Assembly Biosciences, Inc., reported the acquisition of 3,500 restricted stock units following stockholder approval of a plan amendment.
Summary
- Jeanette M. Bjorkquist, Principal Financial Officer and Principal Accounting Officer, was granted 3,500 restricted stock units (RSUs).
- The grant represents 35% of the reporting person's annual equity award.
- The award was contingent upon the June 4, 2026, stockholder approval of an amendment to the 2018 Stock Incentive Plan.
- The RSUs vest in four equal annual installments starting March 29, 2027, through March 29, 2030.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that carries no significant market-moving sentiment.
Positives
- Alignment of executive compensation with long-term shareholder interests through multi-year vesting schedules.
- Successful stockholder approval of the 2018 Stock Incentive Plan amendment, providing necessary equity capacity for compensation programs.
Negatives
- None identified in this filing.
Risks
- Vesting of the RSUs is contingent upon the reporting person maintaining continuous service with the company through each vesting date.
Future Outlook
The reporting person will continue to vest in the granted RSUs annually through March 2030, provided continuous service is maintained.
Industry Context
StockSavvy.ai notes that this filing reflects standard corporate governance practices regarding executive equity compensation and the necessity of shareholder approval for incentive plan expansions in the biotechnology sector.
Comparison to Industry Standards
- The use of multi-year vesting schedules (four years) is consistent with standard industry practices for executive retention in the biotech sector.
- The requirement for shareholder approval for equity plan amendments aligns with typical corporate governance standards for NASDAQ-listed companies.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Stock Incentive Plan Amendment | Stockholders approved an amendment to the 2018 Stock Incentive Plan to increase authorized shares. | 06/04/2026 | Provides the company with additional capacity to issue equity-based compensation to employees and executives. |
Stakeholder Impact
- Shareholders: Dilution impact is managed through the approved plan amendment.
- Employees/Executives: Reinforces retention strategy through equity-based incentives.
Next Steps
- Vesting of the first installment of RSUs on March 29, 2027.
Key Dates
| Date | Description |
|---|---|
| 03/29/2026 | Date of initial RSU grant approval. |
| 06/04/2026 | Stockholder approval of the Plan Amendment, making RSUs issuable. |
| 06/05/2026 | Filing date of the Form 4. |
| 03/29/2027 | First vesting date for the RSU grant. |
Keywords
ASMB, Assembly Biosciences, Form 4, Insider Trading, Equity Compensation, Restricted Stock Units, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.